JP Morgan Chase
VIR icon

JP Morgan Chase’s Vir Biotechnology VIR Stock Holding History

JP Morgan Chase’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.45M Buy
1,117,516
+698,913
+167% +$5.57M ﹤0.01% 2735
2025
Q4 		$2.52M Sell
418,603
-30,915
-7% -$184K ﹤0.01% 3908
2025
Q3 		$2.57M Buy
449,518
+6,143
+1% +$31.4K ﹤0.01% 3887
2025
Q2 		$2.23M Buy
443,375
+4,069
+0.9% +$21.8K ﹤0.01% 3829
2025
Q1 		$2.85M Sell
439,306
-1,367,711
-76% -$12.2M ﹤0.01% 3600
2024
Q4 		$13.3M Buy
1,807,017
+720,690
+66% +$5.68M ﹤0.01% 2432
2024
Q3 		$8.14M Sell
1,086,327
-168,971
-13% -$1.47M ﹤0.01% 2782
2024
Q2 		$11.2M Buy
1,255,298
+792,051
+171% +$7.6M ﹤0.01% 2362
2024
Q1 		$4.69M Buy
463,247
+236,700
+104% +$2.41M ﹤0.01% 3160
2023
Q4 		$2.28M Buy
226,547
+71,557
+46% +$654K ﹤0.01% 3740
2023
Q3 		$1.45M Sell
154,990
-78,529
-34% -$1.12M ﹤0.01% 3800
2023
Q2 		$5.73M Buy
233,519
+107,164
+85% +$2.69M ﹤0.01% 2759
2023
Q1 		$2.94M Sell
126,355
-23,264
-16% -$595K ﹤0.01% 3254
2022
Q4 		$3.79M Buy
149,619
+65,984
+79% +$1.62M ﹤0.01% 3056
2022
Q3 		$1.61M Buy
83,635
+679
+0.8% +$17.3K ﹤0.01% 3644
2022
Q2 		$2.11M Buy
82,956
+2,983
+4% +$69.6K ﹤0.01% 3493
2022
Q1 		$2.06M Sell
79,973
-101,849
-56% -$3.02M ﹤0.01% 3726
2021
Q4 		$7.61M Sell
181,822
-754
-0.4% -$29.5K ﹤0.01% 2690
2021
Q3 		$7.95M Sell
182,576
-27,652
-13% -$1.2M ﹤0.01% 2607
2021
Q2 		$9.94M Buy
210,228
+89
+0% +$4.05K ﹤0.01% 2441
2021
Q1 		$10.8M Buy
210,139
+64,841
+45% +$3.49M ﹤0.01% 2298
2020
Q4 		$3.89M Buy
145,298
+27,775
+24% +$903K ﹤0.01% 3006
2020
Q3 		$4.43M Sell
117,523
-4,008
-3% -$173K ﹤0.01% 2674
2020
Q2 		$4.98M Sell
121,531
-124
-0.1% -$4.16K ﹤0.01% 2463
2020
Q1 		$4.17M Buy
121,655
+21,914
+22% +$589K ﹤0.01% 2418
2019
Q4 		$1.25M Buy
+99,741
New +$1.34M ﹤0.01% 3691

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

JP Morgan Chase's VIR Position: Q1 2026 in Review

JP Morgan Chase increased its Vir Biotechnology (VIR) stake by 167% in Q1 2026, buying an estimated $5.57M and bringing the position to 1,117,516 shares worth $9.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

JP Morgan Chase first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $13.3M in Q4 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • JP Morgan Chase held 1,117,516 shares of Vir Biotechnology worth $9.45M as of Q1 2026.
  • JP Morgan Chase bought 698,913 Vir Biotechnology shares in Q1 2026, an estimated $5.57M.
  • Vir Biotechnology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2735 holding.
  • JP Morgan Chase first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • JP Morgan Chase's Vir Biotechnology position peaked at $13.3M in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.